Table 4.
Non-trial clinical studies for platinum-resistant ovarian cancer.
| Year | Chemotherapy regimen | Subjects | RR (%) |
|---|---|---|---|
| 2009 | paclitaxel + carboplatin (extended weekly)32 | 20 | 60 |
| 2006 | paclitaxel (weekly)42 | 32 | 53 |
| 2007 | irinotecan + etoposide80 | 27 | 44.4 |
| 2008 | bevacizumab + cyclophosphamide51 | 9 | 44 |
| 2007 | paclitaxel + carboplatin (dose-dense)33 | 8 | 37.5 |
| 2006 | bevacizumab + cytotoxic agent*,52 | 23 | 34.8 |
| 2009 | gemcitabine + pemetrexed81 | 10 | 30 |
| 2006 | irinotecan (weekly)82 | 28 | 29 |
| 2009 | gemcitabine + pegylated liposomal doxorubicin83 | 35 | 28.6 |
| 2008 | gemcitabine + pegylated liposomal doxorubicin (biweekly)84 | 18 | 28 |
| 2009 | gemcitabine + cisplatin + ifosamide36 | 16 | 25 |
| 2008 | gemcitabine (fixed dose)85 | 41 | 22 |
| 2008 | docetaxel + imatinib86 | 23 | 21.7 |
| 2008 | topotecan (weekly)87 | 69 | 20.3 |
| 2008 | topotecan + navelbine8 | 22 | 18 |
| 2007 | tamoxifen88 | 29 | 10 |
| 2008 | topotecan (weekly)89 | 22 | 9.1 |
| 2005 | carboplatin35 | 34 | 5.9 |
| 2006 | gemcitabine90 | 21 | 4.7 |
| 2009 | 2-methoxyestradiol91 | 18 | 0 |
Analysis of 20 non-trial clinical studies published between January 2005 and March 2010.
*
combined cytotoxic agents include in the study included: cyclophosphamide (65%), 5-fluorouracil (26%), docetaxel (4%), and gemcitabine + liposomal doxorubicin (4%).
Abbreviations: Subjects, number of patients enrolled in the study; and RR, response rate (complete response rate + partial response rate or objective response rate if response rate is not available).